Aspirin for the Primary Prevention of Myocardial Infarction
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Under the somewhat ill-defined rubric "Special Report," a preliminary report from the Physicians' Health Study, a double-blinded, controlled trial of aspirin in the Physicians’ Health Study is published.
Abstract
Under the somewhat ill-defined rubric "Special Report," we publish in this week's issue a preliminary report from the Physicians' Health Study, a double-blinded, controlled trial of aspirin in the prevention of cardiovascular disease and of beta carotene in the prevention of cancer.1 After more than 59,000 volunteers were screened, 22,000 male U.S. physicians 40 to 84 years of age were entered in the trial and randomly assigned to receive one of four treatments: (1) buffered aspirin (325 mg) and beta carotene (50 mg), (2) buffered aspirin and beta carotene placebo, (3) aspirin placebo and beta carotene, and (4) aspirin placebo . . .